Tilray, Inc. (TLRY) closed the most recent trading day at $75.13, moving -0.52% from the previous trading session. This change was narrower than the S&P 500's daily loss of 1.91%. At the same time, the Dow lost 2.02%, and the tech-heavy Nasdaq lost 2.26%.
Heading into today, shares of the company had lost 29.6% over the past month, lagging the Medical sector's gain of 0.32% and the S&P 500's loss of 2.51% in that time.
TLRY will be looking to display strength as it nears its next earnings release, which is expected to be February 12, 2019.
Investors might also notice recent changes to analyst estimates for TLRY. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 19.58% lower within the past month. TLRY is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 94, putting it in the top 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.